The size of the Global Thin Film Drugs Market is valued at USD 20.97 billion in 2021 and is expected to reach USD 34.55 billion by 2026 and anticipated to grow at 10.50% CAGR during the forecast period 2021 to 2026.
Oral thin films are a new invention by pharmaceutical researchers that delivers drugs through absorption or dissolution.
Most of the drug manufacturing industries are involving in dissolving oral thin films. Children, elder people, bedridden and emetic patients who suffer from neurological disorders face problems with the intake of medicine in the solid dosage form.
According to FDA, Pharma Compass article published in the year 2018, the FDA has approved 46 new drugs in the record. Belbuca and Bunavail are the last two products approved by FDA under are 505(b) (2).
Thin-film drugs are made of hydrophilic polymers that readily dissolve in the buccal cavity. These drugs are administered orally and enter the systemic circulation of the body upon absorption on the tongue.
Drivers & Restrains
The investments that are growing based on the research and development by the manufacturing companies are driving the market forward. The increase in the widespread or not tending to spread the treatment is the factor that drives the market forward. The advanced technology related to the OTF drugs market is increasing worldwide, which is one of the major factors that surge up the market.
The growing demand for successful profits producing drug delivery systems, and researches develop new kinds of polymer thin films are the factors that drive the market growth. Also, the funds from different organizations and the government for the manufacturing industries are leveling up the growth rate of the thin-film market.
The growing demand for efficient drug delivery systems has amplified the uptake of thin-film drugs due to their efficiency and effectiveness. The convenience of transportation and storage has encouraged patients to opt for these drugs. Thin-film drugs also permit precise dosages to accomplish desired outcomes and thereby aid the Global Thin Film Drugs Market growth. The growing investments in research and development of newer polymeric thin films as a method of drug delivery have also invigorated the market growth.
Thin-film drugs are poised to gain attention in the healthcare industry as eliminate the drawbacks associated with conventional forms of dosages such as the inconvenience of administration, lower bioavailability, and patient non-compliance among others.
Availability of alternate drugs at a lower cost is one of the major factors hampering the market growth. Also, the cost that is associated with the treatment in the thin films drug market is expensive, and this is one of the factors that hinder the market.
The need for a very large amount of research investments and challenges that are related to the process of developing the new drugs may restrain the growth of the thin film drugs market. Factors like strict rules and guidelines to be followed, and lengthy processes for the need of approvals are the ones that may hamper the market demand.
On the other hand, the inability of the usage of oral thin films needs to be applied in high dosages can cause ulcers and itching of mucosa that limits the market growth.
Recent Market Developments
Market Size Available
2021 to 2026
2021 to 2026
By Product, Disease Indication, Distribution Channel and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
Market Leaders Profiled
Pfizer Inc., Novartis AG, Wolters Kluwer, Solvay, Allergan plc., Sumitomo Dainippon Pharma Co. Ltd., Indivior Plc., MonoSol Rx, IntelGenx Corp., ZIM Laboratories Limited, and IntelGenx Corp.
This research report on the Global Thin Film Drugs Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2026.
Thin Film Drugs Market Analysis – By Product
On the basis of product, in 2018, the oral thin film sub-segment held the largest share of the Product market segment followed by a transdermal thin film.
Thin Film Drugs Market Analysis – By Disease Indication
Thin Film Drugs Market Analysis – By Distribution Channel
North America accounted for the largest share of the Thin Film Drugs market owing to factors such as advancements in pharmaceutical research coupled with extensive investments in research and development. Moreover, a steadily rising demand for novel drug delivery is further expected to aid the growth of the regional market.
Companies leading the Global Thin Film Drugs Market profiled in this report are:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Oral Thin Film
22.214.171.124 Sublingual Film
126.96.36.199 Fully Dissolving Dental/Buccal Film
5.1.3 Transdermal Thin Film
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Disease Indication
5.2.4 Opioid Dependence
5.2.5 Nausea and Vomiting
5.2.6 Y-o-Y Growth Analysis, By Disease Indication
5.2.7 Market Attractiveness Analysis, By Disease Indication
5.2.8 Market Share Analysis, By Disease Indication
5.3 Distribution Channel
5.3.2 Hospital Pharmacies
5.3.3 Drug Store
5.3.4 Retail Pharmacies
5.3.7 Y-o-Y Growth Analysis, By Distribution Channel
5.3.8 Market Attractiveness Analysis, By Distribution Channel
5.3.9 Market Share Analysis, By Distribution Channel
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Product
220.127.116.11 By Disease Indication
18.104.22.168 By Distribution Channel
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Product
188.8.131.52 By Disease Indication
184.108.40.206 By Distribution Channel
6.1.5 Market Share Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Product
22.214.171.124 By Disease Indication
126.96.36.199 By Distribution Channel
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Pfizer Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis AG
8.3 Wolters Kluwer
8.5 Allergan plc.
8.6 Sumitomo Dainippon Pharma Co. Ltd.
8.7 Indivior Plc.
8.8 MonoSol Rx
8.9 IntelGenx Corp.
8.10 ZIM Laboratories Limited
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Request Sample to VIew LOT